Back to Journals » ImmunoTargets and Therapy » Volume 14
ImmunoTargets and Therapy
- View all (339)
- Volume 15, 2026 (37)
- Volume 14, 2025 (90)
- Volume 13, 2024 (56)
- Volume 12, 2023 (14)
- Volume 11, 2022 (6)
- Volume 10, 2021 (30)
- Volume 9, 2020 (27)
- Volume 8, 2019 (5)
- Volume 7, 2018 (10)
- Volume 6, 2017 (8)
- Volume 5, 2016 (8)
- Volume 4, 2015 (17)
- Volume 3, 2014 (14)
- Volume 2, 2013 (13)
- Volume 1, 2012 (3)
Archive: Volume 14, 2025
Flow Cytometric Profiling of Peripheral Immune Checkpoints Predicts Prognosis and Reveals PD-1/Treg/IL-10 Crosstalk in B-Cell Lymphoma
Pan B, Li S, Ye R, Zhu J, Tang Y, Li L
ImmunoTargets and Therapy 2025, 14:1555-1568
Published Date: 31 December 2025
TLR9: A Double-Dealing Toll-Like Receptor
Nielsen M, Nishizaki D, Kato S, Kurzrock R
ImmunoTargets and Therapy 2025, 14:1531-1554
Published Date: 30 December 2025
Inhibitors of KAT2A Alleviate the Progression of AKI by Alleviating Macrophage Ferritinophagy
Zuo Z, Gao S, Wang J, Liu Z, Lu Z, Wu H, Huang X, Yang C, Chen J, Liu H, Pan Q, Yang L
ImmunoTargets and Therapy 2025, 14:1515-1529
Published Date: 28 December 2025
Precision Medicine in Asthma: The Role of Biomarkers
Quek E, Horn N, Siddiqui S
ImmunoTargets and Therapy 2025, 14:1479-1513
Published Date: 28 December 2025
Immune-Related Adverse Events of Checkpoint Inhibitors and Human Leukocyte Antigen System: A Review
Kośmider K, Kozakiewicz A, Krawczyk P, Kieszko R, Szklener K, Skórzewska M, Wojas-Krawczyk K, Kalinka E, Milanowski J
ImmunoTargets and Therapy 2025, 14:1455-1478
Published Date: 19 December 2025
Integrative Spatial Transcriptomics and Experimental Validation Reveal UBC-Mediated EMT Associated with Immune Evasion in Hepatocellular Carcinoma
Li X, Qin X, Shi K, Lu G, Tian G, Chen Y, Yao R
ImmunoTargets and Therapy 2025, 14:1437-1454
Published Date: 19 December 2025
Development of a Novel Anti-Siglec-15 Antibody for Tumor Immunotherapy
Liu Q, Li L, Nian S, Sun X, Guo X, Li C, Yang Z, Ye Y, Yuan Q
ImmunoTargets and Therapy 2025, 14:1419-1435
Published Date: 11 December 2025
Durable Tumor Control with Multi-Organ Immune-Related Adverse Events Following Immune Checkpoint Inhibitor and Sequential Radiotherapy in Locally Advanced NSCLC: A Case Report
Zhai M, Liu X, Li Y, Pi G, Bi J, Han G
ImmunoTargets and Therapy 2025, 14:1411-1417
Published Date: 10 December 2025
A Critical Role of DC-SIGN+ Tumor-Associated Macrophages in Colorectal Cancer Immune Evasion and Progression via BCL-3-Mediated PD-L1 Expression
Zhang J, Zhao Y, Wang X, Miao C, Xu W, Wan C, Hu B, Qian F
ImmunoTargets and Therapy 2025, 14:1395-1410
Published Date: 10 December 2025
Neutrophil Extracellular Traps in Sepsis and Sepsis-Related Organ Dysfunction
Yan W, Xu X, Li X, Ma Y, Guo L, Yang J, Jin Z, Zhang J, Li T
ImmunoTargets and Therapy 2025, 14:1373-1393
Published Date: 27 November 2025
The Role of Intestinal Microbiota and Immune System Interactions in Autoimmune Diseases
Yurtseven B, Aydemir E, Ayaz F
ImmunoTargets and Therapy 2025, 14:1347-1372
Published Date: 26 November 2025
Deep Learning Classification of Rheumatoid Arthritis in Hand Radiographs Interpretability Insights and Web Application
Cai K, Dou D, Deng G, Zhan Y, Huang H, Feng Z
ImmunoTargets and Therapy 2025, 14:1333-1345
Published Date: 19 November 2025
Multi-Dimensional Characterization of Programmed Cell Death Patterns for Prognostic Stratification and Therapeutic Insights in Sepsis
Zhou C, Bai Y
ImmunoTargets and Therapy 2025, 14:1313-1331
Published Date: 15 November 2025
Clinical Risk Stratification and Modifiable Risk Factors for Hepatitis B Virus-Related Follicular Lymphoma
Deng Y, Jia Z, Zhang H, Zhang X, Liu L, Wang X, Song H, Zhang Z, Liu C, Zhang Q, Ma J
ImmunoTargets and Therapy 2025, 14:1293-1312
Published Date: 12 November 2025
Emerging Role of MDSCS as Novel Biomarkers and Therapeutic Targets for Cancer Immunotherapy
Silva-Romeiro S, Flores-Campos RDC, Sánchez-León ML, Sánchez-Margalet V, De la Cruz-Merino L
ImmunoTargets and Therapy 2025, 14:1267-1291
Published Date: 10 November 2025
Profiling Shared Cytotoxic Immune Signatures in SLE-Associated Coronary Injury Through Transcriptomics and Machine Learning
Chen Y, Tso SM, Wu F, Xu Y, Cui L
ImmunoTargets and Therapy 2025, 14:1247-1266
Published Date: 4 November 2025
Understanding and Managing Hyper IgE Syndromes
Meric Z, Aydin M, Demir Gumus D, Yucel E, Kiykim A
ImmunoTargets and Therapy 2025, 14:1233-1245
Published Date: 5 November 2025
Soluble Programmed Cell Death-1: A Potential Predictor of HBsAg Loss in Pediatric Patients with Chronic Hepatitis B Undergoing Peginterferon Therapy
Yang G, Gan Y, Xia M, Fu Q, Zhang M, Luo K, Wang Z
ImmunoTargets and Therapy 2025, 14:1223-1231
Published Date: 4 November 2025
Glucose Metabolic Reprogramming of Macrophages Against Mycobacterium tuberculosis Infection
Liu T, Yang Z, Tong J, Gao M, Pang Y
ImmunoTargets and Therapy 2025, 14:1209-1221
Published Date: 31 October 2025
Dramatic Clinical Response to a Novel Form of Cell Therapy SL-28 in a Patient with Prostate Cancer and Bone Metastasis: A Case Report
Tetz V, Kardava K, Shulenbayev O, Vecherkovskaya M, Khodadadi-Jamayran A, Tsirigos A, Tetz G
ImmunoTargets and Therapy 2025, 14:1201-1207
Published Date: 29 October 2025
Sorafenib Combined with Tislelizumab and Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: A Phase II Study
Liang L, Zhou J, Huang J, Guo Y, Zhou Z, Chen Y, Lin L, Hong X, Shi W, Lin Z, Liu J, Zhu K, Huang W, Cai M
ImmunoTargets and Therapy 2025, 14:1187-1200
Published Date: 25 October 2025
Regulatory Mechanisms of Co-Inhibitory Receptors in Tuberculosis Immunity: Implications for Therapeutic Targets
Liu H, Li H, Li S, Shang Y, Tang S, Pang Y
ImmunoTargets and Therapy 2025, 14:1169-1185
Published Date: 24 October 2025
Combination Therapy with Romiplostim, Danazol, and a Thrombopoietin Receptor Agonist for Immune Restoration in Chronic Refractory Immune Thrombocytopenia: A Case Series
Wang SX, Tan GM, Zou ZM, Zou LF, Tu YC, Kong FC, Xie X, Li F
ImmunoTargets and Therapy 2025, 14:1159-1167
Published Date: 22 October 2025
Regulation of Histone Acetylation During Inflammation Resolution
Gong L, Lei J, Zhou Y, Zhang J, Wu L, Chen Y, Liu X, Li Y
ImmunoTargets and Therapy 2025, 14:1145-1158
Published Date: 22 October 2025
Efficacy of Tacrolimus Plus Prednisone as Long-Term Immunosuppressive Therapy for Chronic Inflammatory Demyelinating Polyneuropathy: A Retrospective Cohort Study
Di L, Wen X, Zhu W, Wang M, Lu Y, Xu M, Chen H, Da Y
ImmunoTargets and Therapy 2025, 14:1133-1143
Published Date: 7 October 2025
2B4/CD244 Signaling in Immune Regulation and Its Role in Infection, Cancer, and Immune Tolerance
Yan C, Lu P, Jiang Y, Miao S, Zhao L, Xu X
ImmunoTargets and Therapy 2025, 14:1111-1131
Published Date: 4 October 2025
Efficacy and Safety of Different Sequences for mFOLFIRINOX (or SOXIRI) and Gemcitabine Plus Albumin-Bound Paclitaxel in Unresectable Pancreatic Cancer
Huang S, Huang L, Zhang D, Jiang Q, Wang F, Guo G
ImmunoTargets and Therapy 2025, 14:1097-1110
Published Date: 2 October 2025
Psoriasis Increases the Risk of ANCA Associated Vasculitis: Insights from A Propensity Score-Matched Study
Cui R, Wang Q, Kang ZJ, Du Y, Chen M, Wang YH, Wei JC, Dai S
ImmunoTargets and Therapy 2025, 14:1087-1095
Published Date: 26 September 2025
Targeting ILT4 to Improve Immunotherapy Efficacy in Solid Tumour: From Bench to Bedside
Gao A, Wang S, Sun Y
ImmunoTargets and Therapy 2025, 14:1073-1085
Published Date: 18 September 2025
Anti-CD24 Antibody Plus Liposomal Doxorubicin for the Management of Residual Cancers After Incomplete Radiofrequency Ablation
Liu J, Sun B, Li J, Liu X, Zhang G, Lei Z, Zheng C, Kan X
ImmunoTargets and Therapy 2025, 14:1053-1071
Published Date: 18 September 2025
Prostate Cancer Immunotherapy: Time to Move Beyond Checkpoint Inhibitors
Abel M, Warner AB, Karzai F, Madan RA
ImmunoTargets and Therapy 2025, 14:1041-1052
Published Date: 13 September 2025
Research Progress of Natural Killer Cells in Hashimoto’s Thyroiditis
Wang Y, Yan Z, Miao J, Que H, Shan W
ImmunoTargets and Therapy 2025, 14:1029-1040
Published Date: 12 September 2025
Clinical Outcomes and Hepatic Toxicity of Combined Intensity Modulated Radiotherapy and PD-1 Inhibitors in Child-Pugh Class B Advanced Hepatocellular Carcinoma
Chen L, Liu M, Chen S, Wu Y, Guan S, Li J, Liang S
ImmunoTargets and Therapy 2025, 14:1015-1028
Published Date: 12 September 2025
T Cells Dysfunction in Multiple Myeloma
Cai L, Zuo L, Wang G, Li Q, Ma C, Wu J, Sun C, Hu Y
ImmunoTargets and Therapy 2025, 14:997-1014
Published Date: 11 September 2025
Directed-Complement Activation as a Novel Immunotherapeutic Approach for HER2-Breast Cancer
Seguin-Devaux C, Brandus B, Plesseria JM, Iserentant G, Servais JY, Pitiot A, Kanli G, Behrmann I, Schober R, Zimmer J, Cohen JH, Dervillez X
ImmunoTargets and Therapy 2025, 14:979-995
Published Date: 5 September 2025
B7-H3/CD276: Novel Immune Checkpoint and Jack of All Trades
Larkin B, Nishizaki D, Miyashita H, Lee S, Nikanjam M, Eskander RN, Jensen TJ, Pabla S, Conroy JM, DePietro P, Sicklick JK, Kurzrock R, Kato S
ImmunoTargets and Therapy 2025, 14:967-977
Published Date: 5 September 2025
Efficiency and Safety of HAIC Combined with Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma with Lung Metastasis: A Multicenter Propensity Score Matching Analysis
Chen S, Wang N, Xiao Y, Jiang X, Shi F, Cai H, Tang S, Guo W, Zhuang W
ImmunoTargets and Therapy 2025, 14:953-965
Published Date: 2 September 2025
Machine Learning-Derived Neddylation Gene Signature for Predicting Prognosis and Immunotherapy Benefits in Colorectal Cancer
Yang G, Xiao J, He H, Wang J, Wang Z, Jian L, Chen Q
ImmunoTargets and Therapy 2025, 14:931-952
Published Date: 25 August 2025
Ultrasound-Mediated Non-Specific Splenic Immunopotentiation to Elicit Broad-Spectrum Anti-Neoplastic Effects
Dong W, Wang G, Li S, Wang Q, Li W, Liu H, Liang Y, Zhou Z, He X, Guo W, Yuan J, Chai Y, Geng J, Li Z
ImmunoTargets and Therapy 2025, 14:901-930
Published Date: 24 August 2025
Calcitriol and Tacalcitol Modulate Th17 Differentiation Through Osteopontin Receptors: Age-Dependent Insights from a Mouse Breast Cancer Model
Strzykalska-Augustyniak A, Psurski M, Zachary H, Filip-Psurska B, Kłopotowska D, Milczarek M, Świtalska M, Stachowicz-Suhs M, Łabędź N, Ziemblicka A, Gos M, Wietrzyk J
ImmunoTargets and Therapy 2025, 14:877-899
Published Date: 23 August 2025
Fracture-Induced Immunological Cascades Trigger Rapid Systemic Bone Loss via Osteocyte-Regulated Osteoclastogenesis
Sun L, Kuang S, Li Y, Wang G, Sun J, Zhou F, Zhang C
ImmunoTargets and Therapy 2025, 14:849-875
Published Date: 21 August 2025
Comprehensive Insights Into the Role of TRPM4 in Pan-Cancer Progression and Immune Regulation
Chang W, Gao W, Luo B, Chen Y, Wen Z
ImmunoTargets and Therapy 2025, 14:831-848
Published Date: 20 August 2025
PD-L1/ITGB4 Axis Modulates Sensitivity of Hepatocellular Carcinoma to Sorafenib via FAK/AKT/mTOR Signaling Pathway
Zhu T, Cao N, Tu L, Ouyang S, Wang Z, Liang Y, Zhou S, Tang X
ImmunoTargets and Therapy 2025, 14:815-830
Published Date: 13 August 2025
Predicting ICU Admission in Patients with Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy
Su XH, Li WP, Xu XF, Su XL, Liu J, Feng SY, Liu JY, Dong RQ, Ngai IK, Yang L, Xu L, Li ZQ, Li DC, Jiang Y, Peng FH
ImmunoTargets and Therapy 2025, 14:799-814
Published Date: 8 August 2025
Hepatic Metabolic Signature and Its Association with the Response to Immunotherapy in Hepatocellular Carcinoma
Park H, Park S, Park K, Yim SY, Lee JS, Lee SH
ImmunoTargets and Therapy 2025, 14:787-798
Published Date: 23 July 2025
Mitophagy: A Potential Therapeutic Target for Tuberculosis Immunotherapy
Gao S, Yang Z, Yu J, Zhang F, Tang S, Pang Y
ImmunoTargets and Therapy 2025, 14:773-786
Published Date: 22 July 2025
Comparative Effectiveness and Safety of Molecular Targeted Therapy Plus PD-(L)1 with or without TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Study
Liu J, Wang Y, Cui L, Nie Y, Li C, Tan W, Li Y, Bai Y, Wan T, Hu B, Liu Z, Hu M, Wang M, Duan F
ImmunoTargets and Therapy 2025, 14:761-771
Published Date: 17 July 2025
Combination of Radioligand Therapy and Immunotherapy: How to Make It Work in Clinic?
Jiao R, Dadachova E
ImmunoTargets and Therapy 2025, 14:755-759
Published Date: 15 July 2025
Preclinical Evaluation of a B7-H3 Targeting Antibody Enhancing NK Cell-Mediated Cytotoxicity for Ovarian Cancer Treatment
Hagelstein I, Mattern S, Wang K, Haueisen YE, Greiner SM, Englisch A, Staebler A, Singer S, Lutz MS
ImmunoTargets and Therapy 2025, 14:735-753
Published Date: 11 July 2025
Immune Microenvironment on the Molecular Mechanisms and Therapeutic Targets of MAFLD
Jiang Z, Qian B, Xu T, Bai J, Fu W
ImmunoTargets and Therapy 2025, 14:719-733
Published Date: 11 July 2025
Inhibition of Aspartate β-Hydroxylase Enhances Anti-Tumor Immunity
Johari SD, Krausova K, Zucha B, Madureira Trufen CE, Polakova I, Olsen M, Smahel M
ImmunoTargets and Therapy 2025, 14:697-718
Published Date: 7 July 2025
IL-6 Signaling in Immunopathology: From Basic Biology to Selective Therapeutic Intervention
Schumertl T, Lokau J, Garbers C
ImmunoTargets and Therapy 2025, 14:681-695
Published Date: 5 July 2025
Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors
Zhang G, Bai M, Du H, Yuan Y, Wang Y, Fan W, Zhu H, Wu D, He P, Xue B
ImmunoTargets and Therapy 2025, 14:655-680
Published Date: 27 June 2025
Advancing Adjuvant Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review
Akabane M, Chatzipanagiotou OP, Imaoka Y, Schenk A, Pawlik TM
ImmunoTargets and Therapy 2025, 14:631-654
Published Date: 25 June 2025
Immunotargets and Therapy for Systemic Lupus Erythematosus
Mok CC
ImmunoTargets and Therapy 2025, 14:605-629
Published Date: 24 June 2025
TGF-β Decreases NK Cell Mobility and Cytotoxic Efficacy in Complex in vitro Models of the Leukemia Microenvironment
Švubová V, Janstová L, Jedlička M, Mašínová E, Szabová J, Feglarová T, Kuglerová K, Bosáková V, Brodská B, Boráková K, Kundrát D, Trsová I, Böhmová M, Kuželová K, Hrdý J, Gašová Z, Vydra J, Dostálová Merkerová M, Hortová-Kohoutková M, Frič J
ImmunoTargets and Therapy 2025, 14:589-604
Published Date: 18 June 2025
Prognostic Significance of Circulating Immune Subset Counts in Nasopharyngeal Carcinoma
Xie H, Zhang L, Chen L, Zhou W, Zhang L, Su Y, Li B, Ding P, Xiao Y, Lu T, Gong X, Li J
ImmunoTargets and Therapy 2025, 14:577-587
Published Date: 17 June 2025
The Regulatory Network of Transcription Factors in Macrophage Polarization
Liu J, Wang M, Zhao Y
ImmunoTargets and Therapy 2025, 14:555-575
Published Date: 6 June 2025
JAK-STAT Signaling in Autoimmunity and Cancer
Parveen S, Fatma M, Mir SS, Dermime S, Uddin S
ImmunoTargets and Therapy 2025, 14:523-554
Published Date: 11 May 2025
How to Choose Treatment Regimens for Idiopathic Membranous Nephropathy Patients with PLA2R-Negative: A Single-Center Retrospective Cohort Study
Zhou Z, Zou Y, Ke B, Shen W
ImmunoTargets and Therapy 2025, 14:515-522
Published Date: 6 May 2025
Cell-Based Therapeutic Strategies for Autoimmune Diseases
Quero FB, Troncoso-Bravo T, Farías MA, Kalergis AM
ImmunoTargets and Therapy 2025, 14:501-514
Published Date: 28 April 2025
Anti-GAD65 Antibodies Related Refractory Epilepsy Successfully Treated with Tocilizumab: A Case Report and Systematic Literature Review
Chen S, Kessi M, Tan J, He F, Zhang C, Yin F, Yang L, Peng J
ImmunoTargets and Therapy 2025, 14:491-500
Published Date: 18 April 2025
Integration of scRNA-Seq and Bulk RNA-Seq Identifies Circadian Rhythm Disruption-Related Genes Associated with Prognosis and Drug Resistance in Colorectal Cancer Patients
Tao Y, Li J, Pan J, Wang Q, Ke RW, Yuan D, Wu H, Cao Y, Zhao L
ImmunoTargets and Therapy 2025, 14:475-489
Published Date: 11 April 2025
A Case Series of Anti-Metabotropic Glutamate Receptor 2 Antibody-Related Diseases with Distinct Neurological Involvement
Zhang Z, Deng X, Guo D, Zhao J, Li J, He F, Yang L, Peng J
ImmunoTargets and Therapy 2025, 14:465-474
Published Date: 9 April 2025
Selective Deletion of HLA-B, and -C Class I Genes Promotes Immunocompatibility of Humanized Skin Graft Model
Cobos-Figueroa L, Notario L, Mir C, Molpeceres C, Lauzurica S, López D, Lorente E, Lauzurica P
ImmunoTargets and Therapy 2025, 14:451-463
Published Date: 9 April 2025
Recombinant Antithrombin Alleviated Pulmonary Injury and Inflammation in LPS-Induced ARDS by Inhibiting IL17a/NF-κB Signaling
Yang C, Fu C, Wang M, Zheng J, Gao Y, Zhu H, Li H, Li D, Guo L, Yu B, Dai Q
ImmunoTargets and Therapy 2025, 14:433-449
Published Date: 7 April 2025
Cytokine Couture: Designer IL2 Molecules for the Treatment of Disease
Dashwood A, Ghodsinia AA, Dooley J, Liston A
ImmunoTargets and Therapy 2025, 14:403-431
Published Date: 4 April 2025
Comprehensive Analyses of Single-Cell and Bulk RNA Sequencing Data From M2 Macrophages to Elucidate the Immune Prognostic Signature in Patients with Gastric Cancer Peritoneal Metastasis
Tang Q, Tang L, Wang X, Zhang Y, Liu W, Yang T, Wu Y, Ma Y, Lei T, Song W
ImmunoTargets and Therapy 2025, 14:383-402
Published Date: 4 April 2025
Interplay Between Insulin Resistance and Immune Dysregulation in Type 2 Diabetes Mellitus: Implications for Therapeutic Interventions
Berbudi A, Khairani S, Tjahjadi AI
ImmunoTargets and Therapy 2025, 14:359-382
Published Date: 3 April 2025
Recent Advances in Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer
Corti C, Koca B, Rahman T, Mittendorf EA, Tolaney SM
ImmunoTargets and Therapy 2025, 14:339-357
Published Date: 3 April 2025
A High-Throughput, Three-Dimensional Multiple Myeloma Model Recapitulating Tumor-Stroma Interactions for CAR-Immune Cell-Mediated Cytotoxicity Assay
Luanpitpong S, Janan M, Poohadsuan J, Rodboon N, Samart P, Rungarunlert S, Issaragrisil S
ImmunoTargets and Therapy 2025, 14:321-338
Published Date: 30 March 2025
Tumor Immunotherapy Targeting B7-H3: From Mechanisms to Clinical Applications
Guo Y, Wang X, Zhang C, Chen W, Fu Y, Yu Y, Chen Y, Shao T, Zhang J, Ding G
ImmunoTargets and Therapy 2025, 14:291-320
Published Date: 27 March 2025
Causal Association Between Circulating Inflammatory Proteins and Autoimmune Liver Disease: a Bidirectional Two-Sample Mendelian Randomization Study
Leng L, Li Y, Xu T, Shen J, Li L, Li X
ImmunoTargets and Therapy 2025, 14:279-289
Published Date: 26 March 2025
Lysyl Oxidase-Like 1 (LOXL1) Up-Regulation in Chondrocytes Promotes M1 Macrophage Activation in Osteoarthritis via NF-κB and STAT3 Signaling
Jiang Y, Wang S, Zhu W, Liu X, Yang Y, Huo L, Ye J, Ma Y, Zhou Y, Yang Z, Mao J, Wang X
ImmunoTargets and Therapy 2025, 14:259-278
Published Date: 24 March 2025
Myeloid Cells in the Immunosuppressive Microenvironment as Immunotargets in Osteosarcoma
Sholevar CJ, Liu NM, Mukarrama T, Kim J, Lawrence J, Canter RJ
ImmunoTargets and Therapy 2025, 14:247-258
Published Date: 19 March 2025
Exploring the Association Between Immune Cell Phenotypes and Osteoporosis Mediated by Inflammatory Cytokines: Insights from GWAS and Single-Cell Transcriptomics
Kuang S, Ma X, Sun L, Wang C, Li Y, Wang G, Sun J, Zhou F, Zhang C
ImmunoTargets and Therapy 2025, 14:227-246
Published Date: 17 March 2025
Conversion of T Effector Cells Into T Regulatory Cells in Type 1 Diabetes/Latent Autoimmune Diabetes of Adults by Inhibiting eIF5A and Notch Pathways
Rafiqi SI, Aldasouqi A, Paparodis RD, Dewan S, Farooqi A, Faisal S, Nemat Y, Salim N, Qureshi S, Mahmood A, Tovar Y, Jun JY, Kalinoski AL, Mirmira RG, Jaume JC, Imam S
ImmunoTargets and Therapy 2025, 14:205-226
Published Date: 13 March 2025
Development and Characterization of 4A7: A High-Affinity Monoclonal Antibody Targeting Claudin18.2
Wu Y, Tian J, Zhou Y, Zhang R, Gao X, Luo L
ImmunoTargets and Therapy 2025, 14:189-203
Published Date: 11 March 2025
Dissecting Causal Relationship Among Immune Cells, Plasma Metabolites and Coronary Atherosclerosis: A Mendelian Randomization Study
Cao Q, Liu J, Sun J, Qian S, Song J, Zheng H, Wen J, Zheng B
ImmunoTargets and Therapy 2025, 14:175-188
Published Date: 6 March 2025
The Effects of M2 Macrophages-Derived Exosomes on Urethral Fibrosis and Stricture in Scar Formation
Ren X, Wang Z, Wang J, Li X, Wei H, Liu C, Liu S, Zhu Y, Feng C, Yin Y, Tian Y, Wu M, Zeng X
ImmunoTargets and Therapy 2025, 14:151-173
Published Date: 4 March 2025
Increased Risk of Dermatomyositis in Patients with Psoriasis: A Retrospective Cohort Study
Chen M, Tian N, Cui R, Zhang H, Wang Q, Tong Q, Chen Z, Wang YH, Wei JC, Dai SM
ImmunoTargets and Therapy 2025, 14:139-149
Published Date: 1 March 2025
Integrated Profiling Delineated KIF18A as a Significant Biomarker Associated with Both Prognostic Outcomes and Immune Response in Pancreatic Cancer
Nan K, Zhang L, Zou Y, Geng Z, Huang J, Peng Y, Yin S, Zhang M
ImmunoTargets and Therapy 2025, 14:123-138
Published Date: 28 February 2025
Adaptation of Natural Killer Cells to Hypoxia: A Review of the Transcriptional, Translational, and Metabolic Processes
Chang TD, Chen YJ, Luo JL, Zhang C, Chen SY, Lin ZQ, Zhang PD, Shen YX, Tang TX, Li H, Dong LM, Tang ZH, Chen D, Wang YM
ImmunoTargets and Therapy 2025, 14:99-121
Published Date: 18 February 2025
Genetic and Plasma Proteomic Approaches to Identify Therapeutic Targets for Graves’ Disease and Graves’ Ophthalmopathy
Ke C, Yu Y, Li J, Yu Y, Sun Y, Wang Y, Wang B, Lu Y, Tang M, Wang N, Chen Y
ImmunoTargets and Therapy 2025, 14:87-98
Published Date: 7 February 2025
Identification of EARS2 as a Potential Biomarker with Diagnostic, Prognostic, and Therapeutic Implications in Colorectal Cancer
Wang L, Deng X, Tang J, Gong Y, Bu S, Li Z, Liao B, Ding Y, Dai T, Liao Y, Li Y
ImmunoTargets and Therapy 2025, 14:65-85
Published Date: 30 January 2025
PD(L)1 Inhibitors Plus Lenvatinib Vs Atezolizumab Plus Bevacizumab Combined With HAIC for Unresectable HCC: A Propensity Score Matching Study
He Z, Chen H, Liang C, Tang X, Jiang L, Xie F, Liu Q, Zheng Y
ImmunoTargets and Therapy 2025, 14:51-63
Published Date: 25 January 2025
Pan-Cancer Analysis of the Prognostic and Immunotherapeutic Value of PDGFB
Bai Y, Wang X, Wang B
ImmunoTargets and Therapy 2025, 14:35-49
Published Date: 23 January 2025
Increased Co-Expression of PD-L1 and CTLA-4 Predicts Poor Overall Survival in Patients with Acute Myeloid Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation
Chen C, Qiu K, Chen J, Wang S, Zhang Y, Wang C, Li Y
ImmunoTargets and Therapy 2025, 14:25-33
Published Date: 20 January 2025
Targeting B and T Lymphocyte Attenuator Regulates Lupus Disease Development in NZB/W Mice
Gherardi L, Aubergeon L, Sayah M, Fauny JD, Dumortier H, Monneaux F
ImmunoTargets and Therapy 2025, 14:7-23
Published Date: 17 January 2025
Daratumumab and Romiplostim Combined Therapy for a Long-Standing Refractory Primary Immune Thrombocytopenia – Case Report
Zoubi I, Warwar A, Perek S, Preis M
ImmunoTargets and Therapy 2025, 14:1-5
Published Date: 6 January 2025